Not available
Quote | Novartis Ag Basel Akt (OTCMKTS:NVSEF)
Last: | $103.14 |
---|---|
Change Percent: | 0.14% |
Open: | $103.14 |
Close: | $102.9999 |
High: | $103.14 |
Low: | $103.14 |
Volume: | 264 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Novartis Ag Basel Akt (OTCMKTS:NVSEF)
2024-07-20 03:50:03 ET Summary The company continues to deliver strong turnover growth and core margin expansion. Ongoing buyback combined with a juicy dividend yield provides downside protection. Positive contributions from newer drug launches. Novartis raised the 2024 core o...
2024-07-19 10:15:54 ET Summary On July 18, Novartis AG released its second-quarter 2024 financial results, which were solid. The company's free cash flow was about $4.62 billion for the second quarter of 2024, up 40% year over year, primarily due to strong sales of its oncology fr...
Message Board Posts | Novartis Ag Basel Akt (OTCMKTS:NVSEF)
Subject | By | Source | When |
---|---|---|---|
Emylers: NVSEF Financials 07/16/2014 01:38:53 Novartis AG Period Ending Dec 31, 2013 Dec 31, 2012 De | Emylers | investorshangout | 07/16/2014 6:38:51 AM |
chartguy89: NVSEF 83.9233 Stock Charts $NVSEF 1 Month Chart | chartguy89 | investorshangout | 03/09/2014 4:04:01 AM |
chartguy89: NVSEF Stock Charts Last: +1.659 Friday, February 28, 2014 at 10:12:45 AM $NVSEF | chartguy89 | investorshangout | 02/28/2014 3:12:56 PM |
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...